DK0950096T3 - Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse - Google Patents

Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse

Info

Publication number
DK0950096T3
DK0950096T3 DK98937112T DK98937112T DK0950096T3 DK 0950096 T3 DK0950096 T3 DK 0950096T3 DK 98937112 T DK98937112 T DK 98937112T DK 98937112 T DK98937112 T DK 98937112T DK 0950096 T3 DK0950096 T3 DK 0950096T3
Authority
DK
Denmark
Prior art keywords
angiogenesis
pro
glu
ser
variant
Prior art date
Application number
DK98937112T
Other languages
English (en)
Inventor
Terence R Jones
Andrew P Mazar
Original Assignee
Angstrom Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angstrom Pharmaceuticals Inc filed Critical Angstrom Pharmaceuticals Inc
Application granted granted Critical
Publication of DK0950096T3 publication Critical patent/DK0950096T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
DK98937112T 1997-07-25 1998-07-24 Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse DK0950096T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/900,327 US5994309A (en) 1997-07-25 1997-07-25 Anti-invasive and anti-angiogenic compositions and methods
PCT/US1998/015437 WO1999005263A1 (en) 1997-07-25 1998-07-24 Anti-invasive and anti-angiogenic urokinase fragments and their use

Publications (1)

Publication Number Publication Date
DK0950096T3 true DK0950096T3 (da) 2007-02-19

Family

ID=25412335

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98937112T DK0950096T3 (da) 1997-07-25 1998-07-24 Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse

Country Status (11)

Country Link
US (5) US5994309A (da)
EP (1) EP0950096B1 (da)
AT (1) ATE342967T1 (da)
AU (1) AU752205B2 (da)
CA (1) CA2269772A1 (da)
CY (1) CY1107051T1 (da)
DE (1) DE69836199T2 (da)
DK (1) DK0950096T3 (da)
ES (1) ES2275309T3 (da)
PT (1) PT950096E (da)
WO (1) WO1999005263A1 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
WO2001078626A1 (en) 2000-04-13 2001-10-25 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
WO2002038799A2 (en) * 2000-11-07 2002-05-16 University Of Victoria Innovation And Development Corporation Detection of proteases and screening for protease inhibitors
WO2002076486A2 (en) 2001-02-05 2002-10-03 Innoventus Project Ab Histidine-rich glycoprotein
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
AU2003231731A1 (en) * 2002-04-15 2003-11-03 American National Red Cross Method for detecting ligands and targets in a mixture
MXPA05005545A (es) * 2002-11-25 2005-10-18 Attenuon Llc Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
IL156566A0 (en) * 2003-06-19 2004-01-04 Hadasit Med Res Service Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
WO2005002526A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CA2539288C (en) 2003-09-15 2015-05-12 Shaker A. Mousa Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
TWI366459B (en) * 2004-09-28 2012-06-21 Ind Tech Res Inst Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US9220788B2 (en) * 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
US20070134739A1 (en) * 2005-12-12 2007-06-14 Gyros Patent Ab Microfluidic assays and microfluidic devices
US8524663B2 (en) * 2006-03-03 2013-09-03 New York University Method for site-specific polyvalent display on polymers
EP2037270A3 (en) * 2006-03-31 2009-03-25 F. Hoffmann-La Roche Ag Tumor models employing green fluorescent protein
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
EP2120913B1 (en) * 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8481273B2 (en) * 2008-06-20 2013-07-09 University Of Delaware Perlecan fragments as biomarkers of bone stromal lysis
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
JP2012519710A (ja) * 2009-03-06 2012-08-30 アングストロム プハルマセウトイカルス インコーポレイテッド 細胞遊走を調整するための組成物、及び方法
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
CA2795698A1 (en) * 2010-03-05 2011-09-09 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
US20190381127A1 (en) 2016-02-02 2019-12-19 Splash Pharmaceuticals, Inc. Combination therapy with a6, chemotherapeutic agents, radiation therapy, or a combination thereof for the treatment of cancer
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
CN107722115A (zh) * 2017-11-29 2018-02-23 吉林大学 一种新型重组蜂毒多肽及其制备方法和应用
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
CN109180822B (zh) * 2018-11-14 2021-08-10 上海交通大学 一种猪链球菌b细胞优势表位串联疫苗及其制备方法
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422090A (en) * 1984-08-13 1995-06-06 Biotechnology Australia, Pty., Ltd. Human PAI-2
IL81879A (en) 1986-03-13 1994-07-31 Biotech Australia Pty Ltd Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
US5073626A (en) * 1988-11-09 1991-12-17 Monsanto Company Affinity purification of plasminogen activator inhibitor I using a modified urokinase
DE69033653T2 (de) 1989-04-07 2001-06-07 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimental Cancerforskning), Kopenhagen Plasminogen-aktivator-rezeptor vom urokinasetyp
DK182289D0 (da) * 1989-04-14 1989-04-14 Francesco Blasi Modifikation af proteiner
WO1991002057A1 (en) 1989-08-09 1991-02-21 Delta Biotechnology Limited Polypeptide production in fungi
GB8919803D0 (en) * 1989-09-01 1989-10-18 Ciba Geigy Pharmaceutical compositions
DE69031271T2 (de) * 1989-12-20 1998-02-26 Biotech Australia Pty Ltd Varianten von pai-2
GB2246779B (en) 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
US5470970A (en) * 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
ATE190501T1 (de) 1992-05-28 2000-04-15 Univ Toledo Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
WO1994028014A2 (en) * 1993-05-28 1994-12-08 Chiron Corporation Peptide inhibitors of urokinase receptor activity
DE69432608T2 (de) 1993-06-01 2004-02-26 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
IT1271684B (it) 1994-07-22 1997-06-04 Consiglio Nazionale Ricerche Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
AU6505996A (en) * 1995-07-31 1997-02-26 Chiron Corporation Peptide analog inhibitors of urokinase receptor activity
AU1210797A (en) * 1996-01-08 1997-08-01 Nissin Food Products Co., Ltd. Cancerous metastasis inhibitor

Also Published As

Publication number Publication date
EP0950096B1 (en) 2006-10-18
DE69836199T2 (de) 2007-09-13
CY1107051T1 (el) 2012-10-24
WO1999005263A1 (en) 1999-02-04
ATE342967T1 (de) 2006-11-15
ES2275309T3 (es) 2007-06-01
AU752205B2 (en) 2002-09-12
US5994309A (en) 1999-11-30
EP0950096A1 (en) 1999-10-20
US6696416B1 (en) 2004-02-24
US7807621B2 (en) 2010-10-05
US8110543B2 (en) 2012-02-07
CA2269772A1 (en) 1999-02-04
DE69836199D1 (de) 2006-11-30
US20110065640A1 (en) 2011-03-17
PT950096E (pt) 2007-02-28
US20090143303A1 (en) 2009-06-04
US20030027768A1 (en) 2003-02-06
AU8590098A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
DK0950096T3 (da) Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse
JP5559087B2 (ja) 胃腸障害の治療のための方法および組成物
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
JP2008501310A6 (ja) 胃腸障害の治療のための方法および組成物
NO20012984L (no) Succinoylamino benzodiazepiner som inhibitorer av AB proteinproduksjon
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
DE60027564D1 (de) Tek-antagonisten
JP5372096B2 (ja) 新規な抗腫瘍化合物
US20080090760A2 (en) Compositions and Methods for Inhibiting Cellular Proliferation
DE60008399D1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
ATE312095T1 (de) Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden
WO2002081507A3 (en) Interferon gamma polypeptide variants
RU2004139053A (ru) Иммуногенные конъюгаты
SE9700244D0 (sv) Novel antibacterial protein
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
DK0938329T3 (da) Immunogen TLP sammensætning
NO961357D0 (no) Nye terapeutisk aktive peptidforbindelser i blodkoagulasjonskaskaden, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
US20210238229A1 (en) Peptide for disease treatment
WO2004089980A3 (en) Therapeutic cancer vaccine
AR030293A1 (es) Una composicion de vacuna que comprende una proteina receptora de fc; un metodo para prepararla; uso de dicha proteina y de un polinucleotido que codifica para dicha proteina y un metodo para tratar o prevenir una infeccion bacteriana
KR20070047576A (ko) 고나도트로핀 방출 호르몬 ｉｉ 작용억제제 및 이의유사체의 용도